⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 15, 2025Open Access

Supplementary Figure S4 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition

Qi Ye Bohan Ma Lei Li Zixi Wang Mingming Lu Jialu Kang Yuzeshi Lei Shan Xu Ke Wang Yanlin Jian Yizeng Fan Bin Wang Jing Liu Yang Gao Jian Ma Lei Li

View Full Paper

Ask AI

Bookmark

Share

Key Points

BRCA2 degradation is induced by the peptide-based PROTAC degrader in prostate cancer cells, enhancing sensitivity to PARP inhibitors.
DDB1 is crucial in mediating the degradation of BRCA2, indicating a potential therapeutic target for metastatic castration-resistant prostate cancer.
This analysis utilized supplementary data to demonstrate the relationship between BRCA2 degradation and PARP inhibition in prostate cancer.
The findings suggest the need for further investigation into PROTAC technologies for improving cancer treatments.

Implication

Supplementary analysis shows BRCA2 degradation in prostate cancer cells via DDB1, suggesting enhanced PARP inhibition.

Abstract

Supplementary Fig. S4. BPD induces BRCA2 degradation in a DDB1-dependent manner. Related to Fig. 3.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ye et al. (2025) studied this question.

synapsesocial.com/papers/68d46ccf31b076d99fa68fb7 https://doi.org/10.1158/0008-5472.30125749

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S3 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
2Supplementary Figure S7 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
3Supplementary Figure S5 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
4Supplementary Figure S2 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025
5Supplementary Figure S1 from A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition2025